Key facts
- This page summarizes Patrick Lamy's Form 4 filing for Akero Therapeutics, Inc. (AKRO).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 13 Jun 2024, 18:04.
Patrick Lamy - 11 Jun 2024 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)
- Reporting relationship
- Senior VP, Commercial Strategy
- Issuer ticker
- AKRO
- Reported as of
- 11 Jun 2024
- Net transaction value
- -$12,883
- SEC form
- 4
- Accepted by SEC
- 13 Jun 2024, 18:04:29 UTC
- Prior SEC filing
- 12 Dec 2023
- Next SEC filing
- 02 Jul 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jonathan Young, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Patrick Lamy filed Form 4 for Akero Therapeutics, Inc. (AKRO) on 13 Jun 2024.
Change
- Previous filing in this sequence was filed on 12 Dec 2023.
- Current net transaction value: -$12,883.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AKRO
transaction
Common Stock
Sale
- Transaction value
- $12,883
- Shares
- -569
- Change %
- -3%
- Price
- $22.64
- Shares after
- 18,562
- Date
- 11 Jun 2024
- Ownership
- Direct
- Footnotes
- F1, F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. Such sales were automatic and not at the discretion of the Reporting Person.
Footnote F2
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $22.640 to $22.760, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Footnote F3
Includes 561 shares acquired under the Akero Therapeutics, Inc. 2019 Employee Stock Purchase Plan on December 29, 2023.